Skip to content

US · CBUS · BIOTECHNOLOGY

Cibus, Inc. (CBUS) intrinsic value and stock valuation

$1.21as of 2026-11-21 · Mkt cap 138.16M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cibus, Inc. DCF and intrinsic value

InvestorsCraft values CBUS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CBUS’s statements →

Cibus, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 cibus.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$3.64M-31.3% 5y CAGRd
20152025
Net income
-$-127.08M
20152025
Free cash flow
-$-51.17M
20152025
Total equity
$21.8M-10% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$3.64M$4.26M$1.82M$160K$26M
Operating income-$-67.46M-$-258.4M-$-318.88M-$-22.37M-$-29.33M
Net income-$-127.08M-$-251.39M-$-267.63M-$-16.89M-$-29.2M
EPSd-$-277.73K-$-1.08M-$-2.59M-$-29.2K-$-50.48K
Operating cash flow-$-50.59M-$-58.04M-$-46.21M-$-19.36M-$-18.81M
Capital expenditure-$-580K-$-810K-$-4.32M-$-1.52M-$-500K
Free cash flow-$-51.17M-$-58.85M-$-50.53M-$-20.88M-$-19.31M
Total assets$305.1M$350.1M$544.4M$22.4M$37.2M
Total debt$268M$36.3M$24.6M$13.9M$17.9M
Net debt$258M$21.9M-$-8.08M$10.5M$4.05M
Total equity$21.8M$97.8M$338.3M$7.23M$14.1M
Cash and short-term investments$9.92M$14.4M$32.7M$3.43M$13.8M
Income statement
20252024202320222021
Revenue$3.64M$4.26M$1.82M$160K$26M
Cost of revenue$5.92M$0.00$400K$1.53M$28.6M
Gross profit-$-2.28M$4.26M$1.42M-$-1.38M-$-2.57M
Research and development expenses$44.2M$50.4M$42.4M$11.6M$11.3M
Selling, general and administrative expenses$26.9M$30.8M$28.9M$9.44M$15.4M
Other expenses-$-5.92M$181.4M$249M$0.00$20K
Operating expenses$65.2M$262.7M$320.3M$21M$26.8M
Cost and expenses$71.1M$262.7M$320.7M$22.5M$55.3M
Interest income$440K$630K$530K$60K$20K
Interest expense$35.5M$34.2M$18.9M$90K$1.43M
Depreciation and amortization$5.92M$6.86M$4.69M$1.53M$2.34M
Ebitda-$-90.77M-$-241.63M-$-314.58M-$-15.21M-$-25.43M
Operating income-$-67.46M-$-258.4M-$-318.88M-$-22.37M-$-29.33M
Total other income/expenses, net-$-64.71M-$-24.29M-$-18.76M$5.48M$130K
Income before tax-$-132.17M-$-282.68M-$-337.64M-$-16.89M-$-29.2M
Income tax expense$30K$30K-$0.00$0.00$0.00
Net income-$-127.08M-$-251.39M-$-267.63M-$-16.89M-$-29.2M
Weighted average shares outstanding$457.6M$232.2M$103.2M$578.5M$578.5M
Weighted average diluted shares outstanding$457.6M$232.2M$103.2M$578.5M$578.5M
Balance sheet
20252024202320222021
Cash and short-term investments$9.92M$14.4M$32.7M$3.43M$13.8M
Net receivables$700K$1.04M$530K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$12.1M$17M$35.2M$4.13M$15.2M
Property, plant and equipment, net$27.9M$44.7M$37.5M$18.1M$21.7M
Goodwill and intangible assets$264.2M$287M$470.3M$160K$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$293M$333.1M$509.2M$18.3M$22M
Total assets$305.1M$350.1M$544.4M$22.4M$37.2M
Accounts payable$8.07M$5.96M$6.13M$340K$1.26M
Short-term debt$3.17M$4.84M$6.95M$460K$370K
Deferred revenue$540K$930K$1.21M$110K$0.00
Total current liabilities$16.9M$19.9M$21.3M$1.66M$4.85M
Long-term debt$264.8M$31.5M$17.7M$13.5M$17.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$266.4M$232.4M$184.8M$13.5M$18.2M
Capital lease obligations$29.8M$35.6M$23.3M$13.9M$17.9M
Total liabilities$283.2M$252.2M$206.1M$15.2M$23.1M
Common stock$80K$10K$10K$10K$0.00
Retained earnings-$-858.25M-$-731.17M-$-479.78M-$-212.15M-$-196.09M
Accumulated other comprehensive income (loss)$40K$10K$10K$0.00$0.00
Total equity$21.8M$97.8M$338.3M$7.23M$14.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$268M$36.3M$24.6M$13.9M$17.9M
Net debt$258M$21.9M-$-8.08M$10.5M$4.05M
Cash flow statement
20252024202320222021
Net income-$-127.08M-$-282.71M-$-267.63M-$-16.89M-$-29.2M
Depreciation and amortization$5.92M$6.86M$4.69M$1.53M$2.34M
Stock-based compensation$8.19M$10.8M$16.1M$4M$2.09M
Change in working capital$2.32M$380K$960K-$-2.88M$7.49M
Accounts receivable$540K-$-510K$1.7M$0.00$4.89M
Inventory$0.00$0.00$0.00$0.00$1.38M
Accounts payable$720K-$-190K$0.00-$-230K-$-360K
Net cash provided by operating activities-$-50.59M-$-58.04M-$-46.21M-$-19.36M-$-18.81M
Investments in property, plant and equipment-$-580K-$-810K-$-4.32M-$-1.52M-$-500K
Acquisitions, net$0.00$0.00$59.4M$0.00$0.00
Net cash used for investing activities-$-580K-$-810K$55.1M-$-1.52M$11.2M
Common stock issued$47.9M$43.9M$18.8M$11.5M$4.38M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$46.7M$40.6M$20.3M$9.99M$3.74M
Net change in cash-$-4.51M-$-18.27M$29.2M-$-10.89M-$-3.87M
Cash at end of period$9.92M$14.4M$32.7M$3.53M$14.4M
Operating cash flow-$-50.59M-$-58.04M-$-46.21M-$-19.36M-$-18.81M
Capital expenditure-$-580K-$-810K-$-4.32M-$-1.52M-$-500K
Free cash flow-$-51.17M-$-58.85M-$-50.53M-$-20.88M-$-19.31M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cibus, Inc.

        Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

        CEO
        Craig Wichner
        Employees
        118
        Beta
        1.65

        Explore

        Frequently asked questions

        What is the intrinsic value of Cibus, Inc. (CBUS)?

        InvestorsCraft does not currently publish an intrinsic value for CBUS. How the IC value is calculated.

        Is CBUS undervalued?

        InvestorsCraft does not publish an undervaluation signal for CBUS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.